Dateline City:
KENILWORTH, N.J.
KEYNOTE-001 Data Served as the Basis for U.S. FDA Filing and Breakthrough Therapy Designation in Advanced NSCLC Across Histologies
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review the supplemental Biologics License Application
(sBLA) for Mercks anti-PD-1 therapy, KEYTRUDA
(pembrolizumab), for the treatment of patients with advanced non-small
cell lung cancer (NSCLC) whose disease has progressed on or after
platinum-containing chemotherapy and an FDA-approved therapy for EGFR or
ALK genomic tumor aberrations, if present.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more